Discovery may help breast cancer treatment

Researchers led by Dr. Debra Auguste, associate professor, biomedical engineering, in the Grove School of Engineering at The City College of New York, have identified a molecule that could lead to developing treatment for one of the most aggressive forms of breast cancer.

Triple negative breast cancers (TNBCs) have a high mortality rate owing to aggressive proliferation and metastasis and a lack of effective therapeutic options. However, Professor Auguste's team, discovered the overexpression of intercellular adhesion molecule-1 (ICAM-1) in human TNBC cell lines and tissues, and demonstrated that it is a potential molecular target and biomarker for TNBC therapy and diagnosis.

"No therapies are available to treat triple negative cells and because of that patients have a poor prognosis," said Professor Auguste, the recipient of a 2014 Presidential Early Career Award for Scientists and Engineers.

The Identification of ICAM-1 as a TNBC target and biomarker may lead to the development of a new strategy and platform for addressing a critical gap in TNBC patient care, she added.


Explore further

Protein linked to invasive spread of triple-negative breast cancer may lead to targeted therapies

More information: PNAS, www.pnas.org/content/111/41/14710.abstract#aff-1
Citation: Discovery may help breast cancer treatment (2014, November 7) retrieved 25 August 2019 from https://medicalxpress.com/news/2014-11-discovery-breast-cancer-treatment.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more